Objective: We compared the prevalence of frailty by HIV serostatus and related biomarkers to the modified frailty phenotype among older individuals in a rural population in South Africa. Methods: Questionnaire data were from a cohort of people living with HIV (PWH) on antiretroviral therapy (ART) and HIV-uninfected people aged 50 years and older sampled from the Africa Health Research Institute Demographic Health and Surveillance area in northern KwaZulu-Natal. The prevalence of frailty was compared using five categories: (1) physical activity; (2) mobility; (3) fatigue; (4) gait speed; and (5) grip strength, and assessed for demographic, clinical, and inflammatory correlates of frailty. Results: Among 614 individuals in the study, 384 (62.5%) were women. The median age at study enrolment was 64 years [Interquartile range (IQR) (58.6-72.0)]. 292 (47.6%) were PWH. 499 (81%) were classified as either pre-frail or frail. 43 (7%) were frail and HIV positive, 185 (30%) were pre-frail and HIV positive, 57 were frail and HIV negative and 214 (35%) were pre-frail and HIV negative. Frailty was similar for HIV negative and PWH (17.7% vs 14.7%, p = 0.72). Women were more likely to be frail (18.3% vs 13.04%, p = 0.16). The prevalence of frailty increased with age for both HIV groups. In the multivariable analysis, the odds of being frail were higher in those aged 70 years and above than those aged between 50 and 59 years (p < 0.001). Females were less likely to be pre-frail than males (p < 0.001). There was no association between any of the inflammatory biomarkers and frailty and pre-frailty. Conclusion: In this population, the prevalence of frailty is similar for PWH and people without HIV, but higher for women than men. These data suggest that the odds of developing frailty is similar for PWH over the age of 50 years, who survive into older age, as for people without HIV.
Objective: We compared the prevalence of frailty by HIV serostatus and related biomarkers to the modified frailty phenotype among older individuals in a rural population in South Africa. Methods: Questionnaire data were from a cohort of people living with HIV (PWH) on antiretroviral therapy (ART) and HIV-uninfected people aged 50 years and older sampled from the Africa Health Research Institute Demographic Health and Surveillance area in northern KwaZulu-Natal. The prevalence of frailty was compared using five categories: (1) physical activity; (2) mobility; (3) fatigue; (4) gait speed; and (5) grip strength, and assessed for demographic, clinical, and inflammatory correlates of frailty. Results: Among 614 individuals in the study, 384 (62.5%) were women. The median age at study enrolment was 64 years [Interquartile range (IQR) (58.6-72.0)]. 292 (47.6%) were PWH. 499 (81%) were classified as either pre-frail or frail. 43 (7%) were frail and HIV positive, 185 (30%) were pre-frail and HIV positive, 57 were frail and HIV negative and 214 (35%) were pre-frail and HIV negative. Frailty was similar for HIV negative and PWH (17.7% vs 14.7%, p = 0.72). Women were more likely to be frail (18.3% vs 13.04%, p = 0.16). The prevalence of frailty increased with age for both HIV groups. In the multivariable analysis, the odds of being frail were higher in those aged 70 years and above than those aged between 50 and 59 years (p < 0.001). Females were less likely to be pre-frail than males (p < 0.001). There was no association between any of the inflammatory biomarkers and frailty and pre-frailty. Conclusion: In this population, the prevalence of frailty is similar for PWH and people without HIV, but higher for women than men. These data suggest that the odds of developing frailty is similar for PWH over the age of 50 years, who survive into older age, as for people without HIV.
Authors: Andrew M Gross; Philipp A Jaeger; Jason F Kreisberg; Katherine Licon; Kristen L Jepsen; Mahdieh Khosroheidari; Brenda M Morsey; Susan Swindells; Hui Shen; Cherie T Ng; Ken Flagg; Daniel Chen; Kang Zhang; Howard S Fox; Trey Ideker Journal: Mol Cell Date: 2016-04-21 Impact factor: 17.970
Authors: Matthew J Feinstein; June-Ho Kim; Prossy Bibangambah; Ruth Sentongo; Jeffrey N Martin; Alexander C Tsai; David R Bangsberg; Linda Hemphill; Virginia A Triant; Yap Boum; Peter W Hunt; Samson Okello; Mark J Siedner Journal: AIDS Res Hum Retroviruses Date: 2016-09-07 Impact factor: 2.205
Authors: Loic Desquilbet; Lisa P Jacobson; Linda P Fried; John P Phair; Beth D Jamieson; Marcy Holloway; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2007-11 Impact factor: 6.053
Authors: Makandwe Nyirenda; Somnath Chatterji; Jane Falkingham; Portia Mutevedzi; Victoria Hosegood; Maria Evandrou; Paul Kowal; Marie-Louise Newell Journal: BMC Public Health Date: 2012-04-02 Impact factor: 3.295
Authors: Sophia Pathai; Stephen D Lawn; Clare E Gilbert; Dagmara McGuinness; Liane McGlynn; Helen A Weiss; Jennifer Port; Theresa Christ; Karen Barclay; Robin Wood; Linda-Gail Bekker; Paul G Shiels Journal: AIDS Date: 2013-09-24 Impact factor: 4.177
Authors: Collin F Payne; Brian Houle; Chido Chinogurei; Carlos Riumallo Herl; Chodziwadziwa Whiteson Kabudula; Lindsay C Kobayashi; Joshua A Salomon; Jennifer Manne-Goehler Journal: Lancet HIV Date: 2022-10 Impact factor: 16.070
Authors: Patrick Nzivo Mwangala; Adam Mabrouk; Ryan Wagner; Charles R J C Newton; Amina A Abubakar Journal: BMJ Open Date: 2021-09-22 Impact factor: 3.006
Authors: Stephen A Klotz; Cesar Egurrola; Maria Love; Mary N Miller; Nicole Bradley; Shannon N Smith; Bijan Najafi; Nafees Ahmad Journal: Int J STD AIDS Date: 2022-04-04 Impact factor: 1.456